Patient-Centered Innovations, Education and Technology for Cancer Care and Cancer Research
JMIR Cancer (JC) is a new peer-reviewed journal with a focus on education, innovation and technology in cancer care and cancer research, as well as in participatory and patient-centred approaches. A sister journal of the Journal of Medical Internet Research (JMIR), the leading eHealth journal with an impact factor of 4.7, the scope of JC is broader and includes non-Internet approaches to improve cancer care and cancer research.
We invite submission of original research, viewpoints, reviews, tutorials, case studies, and non-conventional articles (e.g. open patient education material and software resources that are not yet evaluated but free for others to use/implement).
In our "Patients' Corner", we invite patients and survivors to submit short essays and viewpoints on all aspects of cancer, but in particular suggestions on how to improve the health care system, and suggestions for new technologies, applications and approaches (no article processing fees).
Articles published in JC will be submitted to PubMed and Pubmed Central. JC is open access and there are no publication costs for the first issues.
Nov 24, 2015
Nov 23, 2015
Sep 8, 2015
Aug 18, 2015
Aug 17, 2015
Jun 26, 2015
Jun 25, 2015
May 18, 2015
Apr 14, 2015
Apr 2, 2015
Mar 9, 2015
Mar 2, 2015
Citing this Article
Right click to copy or hit: ctrl+c (cmd+c on mac)
Latest Submissions Open for Peer-Review:View All Open Peer Review Articles
Like or Dislike? Impact of Facebook on Ewing sarcoma treatment.
Date Submitted: Nov 23, 2015
Open Peer Review Period: Nov 24, 2015 - Jan 19, 2016
Background: An increasing number of patients are raising their voice in online forums via social media platforms to exchange health related information. With more than 1 billion international users da...
Background: An increasing number of patients are raising their voice in online forums via social media platforms to exchange health related information. With more than 1 billion international users daily in summer 2015, Facebook is the leading social media platform including medical related issues. Ewing sarcoma mainly affects teenagers and young adults. A large part of this age group uses Facebook. However, little is known about the impact of this modern way of communication via online platforms on Ewing sarcoma patients and their socioenviroment. Objective: The aim of this study was to analyze Ewing sarcoma patients’ and relatives’ behavior on Facebook to draw conclusions regarding the impact of Facebook on Ewing sarcoma treatment. Methods: We examined a Facebook group named “Ewing Sarcoma Awareness” that is used to exchange information for both, patients and relatives regarding Ewing sarcoma. A self-designed questionnaire was used to compare patients’ and relatives’ answers. Additionally we analyzed all processes (posts, likes, threads, links) in the group during 6 consecutive months. Sixty-five members of the Facebook group (26 patients, 39 relatives) out of 2227 international group members participated in our study. Results: More than 70% of all participants reported that they use the group “Ewing Sarcoma Awareness” as a source of information about Ewing sarcoma. Eighty-nine percent agreed a little or a lot, that being in contact with other people affected via the group makes it easier to handle the diagnosis. Twenty percent of all participants reported that the group affected their choice of treatment and in 15% participants were influenced in the selection of their specialist. Only regarding the recommendation of the Facebook-group towards other people affected a significant difference was found comparing patients’ and relatives’ results. During the last 6 months most activities in the group concerned sharing destiny and handling the diagnosis. Fundraising played a minor role. Conclusions: The Facebook group “Ewing Sarcoma Awareness” has a relevant impact for group members regarding their choice of treatment. Moreover, participants turn towards the group to receive mental support in everyday life. Statements made in the group are in part questionable from a medical point of view and its impact on patients’ care needs further evaluation. Clinical Trial: none